The coronavirus can absorb quashed plans to socialize and stroll the canals of Amsterdam whereas at this 300 and sixty five days’s European Society of Cardiology (ESC) Congress, but organizers are promising a historical digital skills that will “all as soon as more, be a celebration of discovery and ground-breaking science.”
“My message — if I in actual fact absorb to set handiest one element why ESC 2020 will likely be a historical tournament — is that the physician working at the Cleveland Sanatorium, who was as soon as planning to back this 300 and sixty five days in Amsterdam, as well to the colleague in a bush health facility in Uganda, who would absorb never absorb dreamed to be half of the ESC Congress, both can absorb for the major time the same receive entry to at the same time to records shared at the worldwide main cardiovascular meeting,” Marco Roffi, MD, co-chair of the scientific program, told theheart.org | Medscape Cardiology.
Taking a page from the American College of Cardiology, which characteristic the digital bar early within the pandemic with its extremely interactive ACC 2020, ESC is taking some 80 Hot Line, medical discover pointers, and special sessions are dwelling with quiz-and-resolution interactions and panel discussions.
The latest COVID-19 study and four new guideline documents — together with tricks about atrial fibrillation (AF), non-ST-segment elevation acute coronary syndromes, sports activities cardiology and exercise in patients with heart problems, and adult congenital coronary heart disease — will likely be featured at the ESC Congress 2020, scheduled for August 29 to September 1.
Displays will likely be shorter and sessions extra centered, but bigger than 500 scientific and academic sessions will likely be streamed as well to to bigger than 4000 abstracts on hand are dwelling or on interrogate as fleshy presentations or e-posters, said Roffi, College Scientific institution of Geneva, Switzerland.
To pull off the digital tournament, a digital studio in Amsterdam will host hundreds of key idea leaders, and ESC employed bigger than 1000 satellite tv for pc studios spherical the enviornment to amass contributions from scientists and experts with the attend of 70 at the back of-the-scenes experts.
Nonetheless, a “strategic resolution” was as soon as made to supply free receive entry to to the tournament and its reveal for 30 days — a technique that has attracted some 58,000 registrants to this level, up from a memoir 32,000 attendees within the waste 300 and sixty five days’s congress in Paris, Roffi said.
“Clearly, the income is per chance not the same as a physical congress, but we felt there was as soon as too great at stake to originate a compromise,” he said. “We imagine we’re the leaders in cardiovascular conferences within the physical ones and we want to withhold this characteristic even within the new generation. And we imagine this is the initiating of a brand new generation in regardless of create will likely be.”
Hot Line Classes 1-3, Saturday (14: 00 CEST)
The Hot Line sessions will characteristic 13 medical trials and kick off with EMPEROR-Reduced, which in contrast the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim/Eli Lilly) added to traditional care in patients with coronary heart failure with reduced ejection piece (HFrEF), with and with out diabetes.
Eli Lilly and Boehringer Ingelheim already announced the trial met its composite major endpoint of lowering cardiovascular (CV) death or HF hospitalization probability however the major points will likely be critical given the SGLT2 inhibitors’ speedy shift beyond diabetes to HF and continual kidney disease (CKD).
Outcomes equipped at ESC 2019 from the landmark DAPA-HF trial ended in the most modern new indication for dapagliflozin (Farxiga, AstraZeneca) for HFrEF within the absence of diabetes. Fresh records will likely be launched in a Sunday Hot Line session taking a discover at the SGLT2 inhibitor amongst diabetic and nondiabetic CKD patients in DAPA-CKD, which was as soon as halted early thanks to overwhelming efficacy.
As the indication developed, the SGLT2 inhibitors grew to turn into in actual fact heart problems treatment, Roffi said, “so your total cardiologists can absorb to turn into accustomed to those brokers.”
Hot Line 2 will see at the oral cardiac myosin inhibitor mavacamten as an alternative to surgical design or percutaneous interventions to treat obstructive hypertrophic cardiomyopathy (HCM). The major-in-class investigational agent is believed to diminish the hypercontractility attribute of HCM by inhibiting excessive actin-myosin putrid-bridges, and it confirmed promise within the most modern half 2 dose-discovering MAVERICK HCM trial.
Investigators are anticipated to flesh out miniature print from the 251-affected person half 3 EXPLORER-HCM trial, which reported purposeful and symptomatic beneficial properties with as soon as-on an ordinary basis dosing in top-line results launched by developer MyoKardia.
“That is basically a progressive manner to treat — expectantly efficiently — this very advanced disease,” Roffi said.
Rounding out the day is the EAST-AFNET 4 trial, which has been almost 10 years within the making and examined whether or not early rhythm adjust with antiarrhythmic treatment and catheter ablation can pause destructive outcomes in patients with AF in contrast with unprecedented care alone per the ESC 2010 AF medication pointers.
Hot Line Classes 4-6, Sunday (14: 00 CEST)
Hot Line 4 aspects the ATPCI glance inspecting the addition of the oral antianginal agent trimetazidine to traditional of care in 6007 patients with angina after latest winning percutaneous coronary intervention.
Subsequent up is POPULAR-TAVI taking a discover at aspirin with or with out clopidogrel in patients present process transcatheter aortic valve implantation (TAVI).
“That is a plight that we absorb got each day within the cath lab after we fabricate a TAVI attributable to we absorb got in entrance of us patients who, by definition, are at high bleeding probability, are inclined, and absorb comorbidities equivalent to renal insufficiencies,” Roffi said. “I worship this very great attributable to it be a in actual fact intellectual glance. No topic the response will likely be of this glance, it’ll affect medical discover.”
Hot Line 6 is devoted to the PARALLAX trial evaluating sacubitril/valsartan (Entresto, Novartis) with individualized medical therapy in 2569 coronary heart failure with preserved ejection piece (HFpEF) patients. The major outcomes are 12-week change in N-terminal pro-brain natriuretic peptide and 24-week change in 6-minute scoot distance.
Hot Line Classes 7-9, Monday (14: 00 CEST)
The next day begins with the timely topic of irritation with the LoDoCo2 trial, whereby 5522 patients with precise coronary artery disease had been randomized to low-dose colchicine 0.5 mg on an ordinary basis or placebo on top of optimum medical therapy. The major composite endpoint is CV death, myocardial infarction (MI), ischemic stroke, and ischemia-pushed revascularization.
Extra colchicine records also will likely be equipped in a slack-breaking science session on Saturday that involves the Australian COPS trial in acute coronary syndromes and new analyses from COLCOT, which demonstrated a 23% good deal within the probability of first ischemic CV events following an MI but no mortality income. The low-label anti-inflammatory drug is also being examined within the nice 6000-affected person half 3 Colchicine Coronavirus SARS-CoV-2 (COLCORONA) trial, anticipated to be completed by the pause of September.
Hot Line 8 switches gears with the delivery-impress randomized HOME-PE trial evaluating outpatient administration of pulmonary embolism (PE) in 1975 purchase out patients per both the simplified Pulmonary Embolism Severity Index (PESI) ranking, featured within the most latest ESC acute PE pointers, or the HESTIA criteria, developed within the HESTIA glance. The tournament-pushed major pause level is the composite of recurrent venous thromboembolism, major bleeding, and all-reason death at 30 days.
Final up on Monday is a brand new analysis on the outcomes of lowering blood force for prevention of CV events valid via diversified BP ranges from the BPLTTC, which is the biggest resource of affected person-level randomized medical trial records, at bigger than 350,000 patients.
Tuesday Hot Line Classes 10-12 (14: 00 CEST)
The final day of the Congress ends with bang, with the randomized BRACE-CORONA trial inspecting the attain of persevering with or suspending angiotensin-changing enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) in 700 patients with SARS-CoV-2 infection.
Though so much of cardiovascular societies together with ESC recommend continuation of renin-angiotensin-aldosterone machine (RAAS) antagonists in COVID-19 patients, randomized records are missing and patients absorb been rattled by early observations suggesting that ACE2 upregulation from RAAS antagonists might per chance amplify the probability of making excessive COVID-19.
“BRACE-CORONA will resolution the quiz that everybody’s been asking, whether or not or not it’s top to mute proceed ARBs and ACE inhibitors in COVID-19 patients. That is a randomized trial and we’re all very racy about it,” Roffi said.
COVID-19 can even be talked about in a slack-breaking science session on Sunday and in three change Q&A sessions scattered over the 4 days.
Rounding out the final Hot Line session is IMPACT-AFib, a claims database analysis of early vs delayed academic interventions to enhance oral anticoagulation use in a whopping 80,000 patients with AF, and REALITY, a terrific-wanted label-effectiveness analysis of liberal vs restrictive transfusion programs in 630 patients with acute MI and anemia.
Notice Patrice Wendling on Twitter: @pwendl. Notice ESC Congress 2020 coverage from theheart.org | Medscape Cardiology on Twitter and Facebook.
